비결핵항산균(NTM, Non-Tuberculous Mycobacteria) 치료제

· Harrison's Principles of Internal Medicine, 20e (2018)

· Goldman-cecil medicine 25th edition(2016)

· Mandell, Douglas and Bennett 8th (2015)

· Murray&Nadel’s textbook of respiratory medicine 6th ed (2016)

· Fishman's Pulmonary Diseases and Disorders, 5e (2014)

· An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases, Am J Respir Crit Care Med Vol 175. pp 367-416, 2007

· 결핵 진료지침(3판) 2017, 대한결핵 및 호흡기학회 결핵 진료지침 개정위원회

· British Thoracic Society (BTS) guidelines for themanagement of non-tuberculous mycobacterial pulmonary disease (NTM-PD), Thorax 2017;72:iii1·ii64

· R. J. WALLACE, Activities of Linezolid against Rapidly Growing Mycobacteria, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2001, p. 764-767

· J.C. Rodriguez Diaz, In vitro activity of new fluoroquinolones and linezolid against nontuberculous mycobacteria, International Journal of Antimicrobial Agents 21 (2003) 585/588

· Zhijian Zhang, In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex, Diagnostic Microbiology and Infectious Disease 90 (2018) 31-34

· Shannon A. Novosad, Treatment of Mycobacterium abscessus Infection, Emerging Infectious Diseases Vol. 22, No. 3, March 2016

· Mario Nosotti et al, Infections after lung transplantation, J Thorac Dis 2018;10(6):3849-3868

· Koh W.J. et al, Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease, Clinical Infectious Diseases 2017;64(3):309-16

· Park.J.et al, Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense, Clinical Infectious Diseases 2017;64(3):301-8

· Lyu J. et al, A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease, Respiratory Medicine (2014) 108, 1706-1712

· Dennis L, Kasper, et al. Harrison's Principles of Internal Medicine, 20th edition, 2018

· Mandell, Douglas, and Bennett's Principles and Practice pf Infectious Diseases, 8th ed, 2015

· Murray and Nadel's Textbook of Respiratory Medicine, 6th edition, 2016

· Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. (Recommendations of the National Institutes of Health(NIH), theCenters for Disease Control and Prevention(CDC), and the HIV Medicine Association of the Infectious Diseases Society of America(HIVMA/IDSA) (Last Updated: May 7, 2013; Last Revised: June 14, 2017)

· Uthman MM et, al. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007191.

· El-Sadr WM et, al. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 2000 Apr 13;342(15):1085-92.

· Pierce, M, Crampton S et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med, 1996 Aug 8;335(6):384-91

· Benson CA et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. 2000 Apr;181(4):1289-97. Epub 2000 Apr 13.

· Havlir DV et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996 Aug 8;335(6):392-8.

· Currier JS et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med. 2000 Oct 3;133(7):493-503.

· Aberg JA et, al. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clin Trials. 2001 Nov-Dec;2(6):453-9.